PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schmidt, A.* ; Hrupka, B.J.* ; van Bebber, F.* ; Sunil Kumar, S.* ; Feng, X.* ; Tschirner, S.K.* ; Aßfalg, M.* ; Müller, S.A.* ; Hilger, L.S.* ; Hofmann, L.I.* ; Pigoni, M.* ; Jocher, G.* ; Voytyuk, I.* ; Self, E.L.* ; Ito, M.* ; Hyakkoku, K.* ; Yoshimura, A.* ; Horiguchi, N.* ; Feederle, R. ; de Strooper, B.* ; Schulte-Merker, S.* ; Lammert, E.* ; Moechars, D.* ; Schmid, B.* ; Lichtenthaler, S.F.*

The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling.

J. Clin. Invest. 134:e170550 (2024)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
The β-secretase BACE1 is a central drug target for Alzheimer's disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet, little is known about physiological BACE2 substrates and functions in vivo. Here, we identify BACE2 as the protease shedding the lymphangiogenic vascular endothelial growth factor receptor 3 (VEGFR3). Inactivation of BACE2, but not BACE1, inhibited shedding of VEGFR3 from primary human lymphatic endothelial cells (LECs) and reduced release of the shed, soluble VEGFR3 (sVEGFR3) ectodomain into the blood of mice, non-human primates and humans. Functionally, BACE2 inactivation increased full-length VEGFR3 and enhanced VEGFR3 signaling in LECs and also in vivo in zebrafish, where enhanced migration of LECs was observed. Thus, this study identifies BACE2 as a modulator of lymphangiogenic VEGFR3 signaling and demonstrates the utility of sVEGFR3 as a pharmacodynamic plasma marker for BACE2 activity in vivo, a prerequisite for developing BACE1-selective inhibitors for a safer prevention of Alzheimer's disease.
Impact Factor
Scopus SNIP
Altmetric
13.300
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Aging ; Alzheimer Disease ; Drug Therapy; Amyloid Precursor Protein; Growth-factor Receptor-3; Beta-site; Computational Platform; Vascular Development; Proteomic Analysis; Randomized-trial; Verubecestat; Morphogenesis; Enrichment
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 0021-9738
e-ISSN 1558-8238
Zeitschrift Journal of Clinical Investigation
Quellenangaben Band: 134, Heft: 16, Seiten: , Artikelnummer: e170550 Supplement: ,
Verlag American Society of Clinical Investigation
Verlagsort 2015 Manchester Rd, Ann Arbor, Mi 48104 Usa
Begutachtungsstatus Peer reviewed
Institut(e) CF Monoclonal Antibodies (CF-MAB)
POF Topic(s) 30201 - Metabolic Health
PSP-Element(e) A-631900-001
Förderungen Helmholtz Association
CiM-IMPRS graduate school
Federal Ministry of Education and Research
Cure Alzheimer's Fund
Institute for the Promotion of Innovation by Science and Technology in Flanders
Alzheimer's Association
Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology
CRC 1348 (DFG)
Deutsche Forschungsgemeinschaft (DFG, German Research foundation)
DOI 10.1172/JCI170550
WOS ID 001307280000029
Scopus ID 85201437442
PubMed ID 38888964
Erfassungsdatum 2024-06-20
[➜Korrektur melden]